SeQuent Scientific Limited: Company Profile

Background

Overview

SeQuent Scientific Limited is India's leading animal health company, ranked among the top 20 animal health companies globally. The company reported a consolidated turnover of ₹13.69 billion and a market capitalization of approximately ₹29.33 billion. With operations in over 90 countries and seven manufacturing facilities, SeQuent Scientific offers a comprehensive range of products and services, including Active Pharmaceutical Ingredients (APIs), Finished Dosage Formulations (FDFs), and analytical services.

Mission and Vision

Mission: To deliver quality products competitively while adhering to high standards of quality, governance, and compliance.

Vision: To be a leading integrated animal health company committed to providing quality veterinary solutions globally.

Core Values

Adaptability: Adjusting to new tasks and appearing flexible in any situation.

Accountability: Acknowledging and taking responsibility for actions and decisions.

Integrity: Acting honestly and respecting one another at all times.

Collaboration: Encouraging teamwork, believing that the whole is greater than the sum of its parts.

Continuous Improvement: Improving systems and procedures for better quality and cost efficiency.

Key Strategic Focus

Core Objectives

SeQuent Scientific aims to advance animal healthcare through innovative research and solutions, addressing unmet needs in the animal health industry by offering products for livestock, poultry, and companion animals.

Areas of Specialization

Animal Health: Providing a comprehensive suite of products, including APIs, FDFs, and analytical services tailored to the global animal health sector.

Analytical Services: Offering analytical and bio-analytical services to support API, pharmaceutical, personal care, and nutraceutical companies.

Key Technologies Utilized

SeQuent Scientific employs advanced technologies in its research and development processes, focusing on innovative and complex formulations for animal health, pharmaceuticals, and agri-business industries.

Primary Markets Targeted

The company serves markets across Europe, Asia, and the Rest of the World, with Europe being a significant contributor to its revenue.

Financials and Funding

Funding History

SeQuent Scientific has raised a total of $17 million over two funding rounds, with the latest round occurring on June 29, 2020.

Recent Funding Rounds

June 29, 2020: Raised $17 million in a post-IPO equity round.

Notable Investors

The Carlyle Group, a global investment firm, holds a significant stake in SeQuent Scientific, with a 52.61% ownership.

Utilization of Capital

The funds raised have been utilized to strengthen SeQuent Scientific's research and development and manufacturing capabilities, with over $100 million invested in the last five years.

Pipeline Development

Key Pipeline Candidates

SeQuent Scientific's product portfolio includes various therapies such as anthelmintics, anti-protozoals, nutraceuticals, NSAIDs, anti-infectives, and dermatology products.

Stages of Development

The company is involved in the development of innovative and complex formulations for animal health, pharmaceuticals, and agri-business industries.

Target Conditions

SeQuent Scientific's products target a range of conditions, including parasitic infections, nutritional deficiencies, and various diseases in livestock and companion animals.

Anticipated Milestones

While specific timelines for anticipated milestones are not detailed, the company's ongoing investment in R&D and manufacturing capabilities indicates a commitment to continuous product development and market expansion.

Technological Platform and Innovation

Proprietary Technologies

SeQuent Scientific has developed proprietary technologies in the production of veterinary APIs and formulations, with its Vizag site being India's only USFDA-approved dedicated veterinary API facility.

Significant Scientific Methods

The company employs advanced scientific methodologies in its R&D processes, focusing on innovative and complex formulations for animal health, pharmaceuticals, and agri-business industries.

Leadership Team

Key Executives

Mr. Rajaram Narayanan: Managing Director and CEO.

Mr. Neeraj Bharadwaj: Non-Executive Director.

Mr. Gregory Andrews: Non-Executive Director.

Dr. Fabian Kausche: Non-Executive Director.

Mr. Milind Sarwate: Independent Director.

Dr. Kamal Sharma: Chairman & Independent Director.

Ms. Revati Kasture: Independent Director.

Dr. Hari Babu Bodepudi: Non-Executive Director.

Mr. Vedprakash Ragate: Executive Director.

Professional Backgrounds and Contributions

Mr. Rajaram Narayanan: As Managing Director and CEO, he has been instrumental in leading SeQuent Scientific's strategic initiatives and growth.

Dr. Kamal Sharma: Serving as Chairman & Independent Director, he brings extensive experience in the pharmaceutical industry, contributing to the company's governance and strategic direction.

Mr. Milind Sarwate: As Independent Director, he provides valuable insights into financial management and corporate governance.

Ms. Revati Kasture: Serving as Independent Director, she offers expertise in regulatory affairs and compliance, ensuring the company's adherence to industry standards.

Competitor Profile

Market Insights and Dynamics

The global animal health market is experiencing significant growth, driven by increasing pet ownership, rising demand for livestock products, and heightened awareness of zoonotic diseases. This growth presents opportunities for companies like SeQuent Scientific to expand their market presence and product offerings.

Competitor Analysis

SeQuent Scientific faces competition from several key players in the animal health sector, including:

Phibro Animal Health: A global animal health and mineral nutrition company.

Ashish Life Science Pvt. Ltd.: An Indian company specializing in animal health products.

Alembic Pharmaceuticals: A diversified pharmaceutical company with a presence in animal health.

These competitors offer similar products and services, contributing to a dynamic and competitive market landscape.

Strategic Collaborations and Partnerships

SeQuent Scientific has engaged in strategic collaborations to enhance its market position and innovation capacity. Notably, the company announced a strategic partnership agreement with Immunostar Inc., USA, in 2021-22, aiming to expand its product offerings and global reach.

Operational Insights

SeQuent Scientific's global footprint, with manufacturing facilities in India, Spain, Brazil, and Turkey, provides a strategic advantage in serving diverse markets. The company's focus on high-quality standards and regulatory compliance differentiates it from competitors, reinforcing its position in the animal health industry.

Strategic Opportunities and Future Directions

SeQuent Scientific is well-positioned to capitalize on the growing global demand for animal health products. The company's ongoing investments in R&D and manufacturing capabilities, along with strategic partnerships, are expected to drive future growth and innovation. Expanding into emerging markets and diversifying its product portfolio present additional opportunities for the company.